How transcription factor mutations shape diabetes risk
Diabetes affects hundreds of millions of people worldwide. The disease features elevated blood glucose levels and disrupted fat and protein metabolism. The musculoaponeurotic fibrosarcoma, or MAF, family of transcription factors regulate various processes in tissue development, including hormone production in pancreatic islet cells. Within this family, MAFA and MAFB are essential for development and maturation of insulin- and glucagon-producing cells.
Previous research showed that MAFA and MAFB expression is affected in diabetes, both Type 1 and Type 2. In addition, a mutation in MAFA that prevents phosphorylation of a key serine residue causes monogenic diabetes. Mutation of the equivalent residue in MAFB leads to a pediatric multisystem disorder. In a recent Journal of Biological Chemistry article, Jeeyeon Cha, Xin Tong and Katie Coate from Vanderbilt University and collaborators in the U.S. examined how mutations in conserved DNA-binding domains of the MAF proteins impact their regulation of the insulin gene. The authors used targeted mutagenesis and artificial intelligence structure prediction using AlphaFold 2 for their analysis.
They found one MAFA variant, with a mutation in the conserved DNA-binding region, that exhibited normal activity. The equivalent mutation in MAFB did not retain normal activity. Therefore, the researchers searched for structural differences between the MAFA and MAFB proteins outside of the DNA-binding region that might also contribute to its activity. Their AlphaFold 2 models showed that the two proteins differed in the C-terminal domains. The researchers created chimeras by exchanging the two C-terminal domains of MAFA and MAFB, which changed how each protein regulated the insulin gene. These results help clarify differences between MAFA and MAFB, which of their domains affect activity and possible ways that they contribute to different disease states.
Future studies will focus on regions of MAFA and MAFB that may interact with other coregulators of the insulin gene.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Avoiding common figure errors in manuscript submissions
The three figure issues most often flagged during JBC’s data integrity review are background signal errors, image reuse and undeclared splicing errors. Learn how to avoid these and prevent mistakes that could impede publication.

Ragweed compound thwarts aggressive bladder and breast cancers
Scientists from the University of Michigan reveal the mechanism of action of ambrosin, a compound from ragweed, selectively attacks advanced bladder and breast cancer cells in cell-based models, highlighting its potential to treat advanced tumors.

Lipid-lowering therapies could help treat IBD
Genetic evidence shows that drugs that reduce cholesterol or triglyceride levels can either raise or lower inflammatory bowel disease risk by altering gut microbes and immune signaling.

Key regulator of cholesterol protects against Alzheimer’s disease
A new study identifies oxysterol-binding protein-related protein 6 as a central controller of brain cholesterol balance, with protective effects against Alzheimer’s-related neurodegeneration.

From humble beginnings to unlocking lysosomal secrets
Monther Abu–Remaileh will receive the ASBMB’s 2026 Walter A. Shaw Young Investigator Award in Lipid Research at the ASBMB Annual Meeting, March 7-10 in Washington, D.C.

Chemistry meets biology to thwart parasites
Margaret Phillips will receive the Alice and C. C. Wang Award in Molecular Parasitology at the ASBMB Annual Meeting, March 7-10 in Washington, D.C.